機関投資家の保有一覧

ORBIMED ADVISORS LLC

持ち方

—

評価額を取得中

届出上位5銘柄の比重

—

保有

115銘柄

ORBIMED ADVISORS LLC は、2026年6月30日の SEC Form 13F で 115 銘柄の保有を報告しました。届出上位には Edgewise Therapeutics、Enliven Therapeutics、Eli Lilly が並び、ヘルスケアにまたがります。下の銘柄名と保有株数は届出に基づきます。

届出上位の10銘柄

1
EW
EWTXEdgewise Therapeutics
ヘルスケア・ 15,518,492 株
—
2
EL
ELVNEnliven Therapeutics
ヘルスケア・ 6,776,632 株
—
3
LL
LLYEli Lilly
ヘルスケア・ 257,900 株
—
4
MB
MBXMBX Biosciences
ヘルスケア・ 3,428,736 株
—
5
AZ
AZNAstraZeneca
ヘルスケア・ 915,700 株
—
6
NT
NTRANatera
ヘルスケア・ 262,000 株
—
7
GH
GHGuardant Health
ヘルスケア・ 583,700 株
—
8
MR
MRKMerck
ヘルスケア・ 663,400 株
—
9
AV
AVBPArriVent BioPharma
ヘルスケア・ 3,027,328 株
—
10
AR
ARGXargenx
ヘルスケア・ 92,880 株
—

残り 105 銘柄をすべて見る ▾

#	銘柄	保有株数	概算評価額
11	CAICaris Life Sciences	2,806,811	—
12	CRVSCorvus Pharmaceuticals	7,165,006	—
13	EWEdwards Lifesciences	834,900	—
14	PRAXPraxis Precision Medicines	230,100	—
15	CGONCG Oncology	972,800	—
16	HUMHumana	164,100	—
17	BSXBoston Scientific	1,483,200	—
18	ODTXOdyssey Therapeutics	3,001,198	—
19	ISRGIntuitive Surgical	157,900	—
20	GPCRStructure Therapeutics	2,209,400	—
21	UNHUnitedHealth Group	161,100	—
22	TMOThermo Fisher Scientific	90,700	—
23	BMYBristol Myers Squibb	925,000	—
24	ASNDAscendis Pharma	244,456	—
25	COGTCogent Biosciences	1,681,300	—
26	ARQTArcutis Biotherapeutics	2,042,000	—
27	ABVXAbivax	546,522	—
28	PRLDPrelude Therapeutics	13,724,571	—
29	MLYSMineralys Therapeutics	2,110,300	—
30	DYNDyne Therapeutics	3,235,684	—
31	ELVElevance Health	114,700	—
32	SYKStryker	159,100	—
33	STTKShattuck Labs	6,306,127	—
34	QUREuniQure	1,807,486	—
35	PVLAPalvella Therapeutics	292,360	—
36	HELPCybin	3,271,400	—
37	QTTBQ32 Bio	4,127,987	—
38	XENEXenon Pharmaceuticals	892,471	—
39	SPRYARS Pharmaceuticals	8,288,510	—
40	KNSAKiniksa Pharmaceuticals International	420,600	—
41	RYTMRhythm Pharmaceuticals	322,900	—
42	UPBUpstream Bio	5,693,589	—
43	URGNUroGen Pharma	676,187	—
44	SNDXSyndax Pharmaceuticals	1,542,000	—
45	KRYSKrystal Biotech	83,200	—
46	WSTWest Pharmaceutical Services	70,600	—
47	ORICOric Pharmaceuticals	2,015,000	—
48	IRONDisc Medicine	357,535	—
49	AXSMAxsome Therapeutics	117,578	—
50	AURAAura Biosciences	3,333,333	—
51	NKTRNektar Therapeutics	465,346	—
52	TRVITrevi Therapeutics	1,430,293	—
53	NPCENeuroPace	1,505,125	—
54	SVRASavara	3,959,900	—
55	SYRESpyre Therapeutics	186,145	—
56	WATWaters Corp	40,300	—
57	BCRXBioCryst Pharmaceuticals	1,852,000	—
58	RVMDRevolution Medicines	70,500	—
59	WHWKWhiteHawk Therapeutics	3,934,296	—
60	TVTXTravere Therapeutics	253,000	—
61	LXEOLexeo Therapeutics	3,947,850	—
62	DFTXDefinium Therapeutics	365,400	—
63	BIIBBiogen	61,600	—
64	CMPXCompass Therapeutics	15,219,994	—
65	RLMDRelmada Therapeutics	3,631,195	—
66	SIONSionna Therapeutics	2,555,877	—
67	MNPRMonopar Therapeutics	157,423	—
68	STROSutro Biopharma	743,944	—
69	VERAVera Therapeutics	369,596	—
70	LFSTLifeStance Health	947,400	—
71	CRBPCorbus Pharmaceuticals	1,737,287	—
72	DNTHDianthus Therapeutics	115,000	—
73	TSHATaysha Gene Therapies	2,000,000	—
74	SPRBSpruce Biosciences	200,000	—
75	JANXJanux Therapeutics	524,700	—
76	KROSKeros Therapeutics	759,155	—
77	ERASErasca	495,900	—
78	PHVSPharvaris	205,400	—
79	ANROAlto Neuroscience	257,852	—
80	TARAProtara Therapeutics	2,220,000	—
81	PTGXProtagonist Therapeutics	42,100	—
82	ACETAdicet Bio	844,787	—
83	XLOXilio Therapeutics	592,300	—
84	TECXTectonic Therapeutic	226,600	—
85	AMLXAmylyx Pharmaceuticals	183,400	—
86	BIOABioAge Labs	752,153	—
87	DRUGBright Minds Biosciences	93,000	—
88	IMAImageneBio	909,269	—
89	AORTArtivion	175,000	—
90	ALMSAlumis	548,163	—
91	ALNYAlnylam Pharmaceuticals	17,000	—
92	ZNTLZentalis Pharmaceuticals	1,390,576	—
93	ALXOALX Oncology Holdings	2,866,256	—
94	EYPTEyePoint Pharmaceuticals	1,069,147	—
95	BCAXBicara Therapeutics	191,100	—
96	PALIPalisade Bio	2,333,000	—
97	PTCTPTC Therapeutics	49,100	—
98	ACADACADIA Pharmaceuticals	137,000	—
99	TARSTarsus Pharmaceuticals	35,581	—
100	RAPPRapport Therapeutics	76,616	—
101	BLTEBelite Bio	13,300	—
102	TYRATyra Biosciences	102,000	—
103	EPRXEupraxia Pharmaceuticals	269,000	—
104	NSPRInspireMD	3,133,405	—
105	ACRSAclaris Therapeutics	421,500	—
106	OVIDOvid Therapeutics	747,000	—
107	CYTKCytokinetics	25,800	—
108	AGMBAgomab Therapeutics	192,740	—
109	OCULOcular Therapeutix	220,000	—
110	EVMNEvommune	161,000	—
111	NMRANeumora Therapeutics	2,139,882	—
112	TRAWTraws Pharma	1,203,260	—
113	FBRXFBRX	1,577,705	—
114	CRNXCRNX	999,000	—
115	ATAIATAI	797,500	—

2026年6月30日時点の SEC への Form 13F 届出 (運用資産 $100M 以上の機関投資家が四半期ごとに提出) の集計。届出は四半期末から最大45日遅れで公開されるため、現在の保有と異なる場合があります。概算評価額と構成比は当サイトの株価で計算した参考値です。届出対象外の資産 (米国外上場株・債券など) は含まれません。